- in 2006 by Pfizer, but poor
sales led
Pfizer to
withdraw it in 2007.
Afrezza, a
monomeric inhaled,
ultra rapid-acting
insulin developed by Mannkind...
- inhaler, upon
which was
developed its lead product,
Afrezza (inhalable insulin). The FDA
approved Afrezza on June 27, 2014. On
August 11, 2014
MannKind entered...
- insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza...
- insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza...
- mellitus.
Admelog (insulin lispro), for type 1 and type 2
diabetes mellitus.
Afrezza (Inhalable insulin), for type 1 and type 2
diabetes mellitus.
Amaryl (Glimepiride)...
- insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza...
- insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza...
- insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza...
- insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza...
- insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza...
